Targeted Nutrient Supplement in COPD (NUTRECOVER-trial)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

166 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-02-19

Study Completion Date

2026-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The overall objective is to investigate the efficacy of targeted nutrient supplementation on daily physical activity level as well as generic health status in patients with COPD. Additionally the investigators aim to investigate the relative effect of targeted nutrient supplementation on the recovery after hospitalization for a COPD exacerbation. The secondary objective is to investigate the effect of targeted nutrient supplementation on mental health, physical performance, blood markers, patient related outcomes and gut health. Additionally, a secondary objective is to compare the gut microbiome composition of patients with COPD compared to healthy controls.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Impact of Nutritional Supplementation on Aerobic Performance and Fatigue

NCT02134756

Performance Fatigue

COMPLETED NA

NAD Supplementation Study

NCT03310034

Aging Mitochondrial Function

TERMINATED NA

Effects of a Recovery Supplement on Body Composition, Performance, Muscular Properties, and Wellbeing

NCT05769101

Protein Deficiency Training Group, Sensitivity Fatigue +2 more

COMPLETED NA

Oral Supplement and Acute Resistance Exercise

NCT06801951

Chronic Obstructive Pulmonary Disease

COMPLETED NA

Safety, Tolerance and Efficacy of an Oral Nutritional Supplement in Chronic Heart Failure and Chronic Obstructive Pulmonary Disease Patients

NCT00852020

Cachexia Chronic Obstructive Pulmonary Disease Chronic Heart Failure

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Rationale: Impaired physical and mental health are common features in COPD adversely affecting disease course and quality of life. Furthermore, nutritional status is often impaired due to dietary and plasma nutrient deficiencies, decreased muscle oxidative metabolism and impaired intestinal permeability. The investigators hypothesize that targeted nutrient supplementation can lead to gut-muscle-brain axis-mediated amelioration of physical, cognitive and mental health domains, resulting in a healthier lifestyle, in patients with COPD.

Study design: Randomized, placebo-controlled, double-blind trial.

Nature and extent of the burden and risks associated with participation, benefit and group relatedness: The nutrient supplement is hypothesized to have beneficial effects on general health because it applies physical and mental health domains. The healthy lifestyle counselling aims to improve medical adherence, to address a healthier lifestyle and to manage weight loss which would contribute to improved general health. Risks and inconveniences are limited to the time investment associated with taking the supplements and measuring days. During the test-days various non-invasive measurements as well as minor invasive blood sampling will be performed. The investigators expect no risk of the nutrient supplementation. Healthy controls will only attend a subgroup of baseline measurements which are limited to non-invasive measurements and one minor invasive blood sampling. Healthy controls will not receive the nutritional supplement.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pulmonary Disease, Chronic Obstructive

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Next to the 166 COPD patients that receive the nutritional supplement, a subgroup of 30 healthy controls will be included for baseline comparison of the microbiome composition. These healthy controls will not be included in the intervention arm.

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Group Long-drink

83 COPD patients will receive:

* Targeted nutrient supplementation (Long-drink) once daily
* Counselling once monthly

Group Type EXPERIMENTAL

Targeted nutrient supplementation (Long-drink)

Intervention Type DIETARY_SUPPLEMENT

Once daily for at least 12 months

Counselling

Intervention Type BEHAVIORAL

Counselling on healthy lifestyle (in particular physical activity, smoking cessation) and weight management by motivational interviewing

Group Placebo

83 COPD patients will receive:

* Isocaloric placebo supplement once daily
* Counselling once monthly

Group Type PLACEBO_COMPARATOR

Placebo supplement

Intervention Type DIETARY_SUPPLEMENT

Once daily for at least 12 months

Counselling

Intervention Type BEHAVIORAL

Counselling on healthy lifestyle (in particular physical activity, smoking cessation) and weight management by motivational interviewing

Healthy control group

30 healthy controls will be included for baseline comparison of the microbiome composition. These healthy controls will only perform a subset of baseline measurements and will not be included in the intervention.

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Targeted nutrient supplementation (Long-drink)

Once daily for at least 12 months

Intervention Type DIETARY_SUPPLEMENT

Placebo supplement

Once daily for at least 12 months

Intervention Type DIETARY_SUPPLEMENT

Counselling

Counselling on healthy lifestyle (in particular physical activity, smoking cessation) and weight management by motivational interviewing

Intervention Type BEHAVIORAL

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Nutritional supplementation Dietary supplement Nutritional supplement Food supplement Non-active supplement Motivational interviewing

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* COPD patients with moderate to very severe disease stage according to GOLD criteria (i.e. GOLD stage II-IV);
* Medically stable.

* Forced expiratory volume in 1 second/Forced vital capacity \> 0.7;
* Medically stable.

Exclusion Criteria

* Age \<18 years;
* Allergy or intolerance to components of the study product;
* Not willing or not able to quit vitamin D or fatty acid supplement intake;
* Investigator's uncertainty about the willingness or ability of the patient to comply with the protocol requirements (e.g. leg amputation) or patients suffering from other acute or unstable chronic diseases that will compromise the study outcome (e.g. active cancer requiring treatment);
* Participation in any other study involving investigational or marketed products concomitantly or within four weeks prior to entry into the study;
* Patients with terminal illness;
* Recent hospital admission (\<4 weeks prior to the start of the study);
* Temporary oral steroid or antibiotics use due to a COPD exacerbation in the last 4 weeks;
* Lung malignancy in the previous 5 years;
* Diagnosis of dementia or neurodegenerative disease (e.g., Alzheimer's disease, Parkinson's disease, Huntington's chorea, frontotemporal dementia) in the medical records;
* Recent diagnosis of cerebral conditions (\<1 year e.g. cerebral infarction, hemorrhage, brain tumors, transient ischemic attack) in the medical records;
* Any medical condition that significantly interferes with digestion and/or gastrointestinal function (e.g. short bowel syndrome, inflammatory bowel disease, gastric ulcers, gastritis, (gastro)-enteritis, GI-cancer) as judged by the investigator.

* Age \<18 years;
* Investigator's uncertainty about the willingness or ability of the patient to comply with the protocol requirements (e.g. leg amputation) or patients suffering from other acute or unstable chronic diseases that will compromise the study outcome (e.g. active cancer requiring treatment);
* Participation in any other study involving investigational or marketed products concomitantly or within four weeks prior to entry into the study;
* Patients with terminal illness;
* Recent hospital admission (\<4 weeks prior to the start of the study);
* Temporary antibiotics use in the last 4 weeks;
* Lung malignancy in the previous 5 years;
* Diagnosis of dementia or neurodegenerative disease (e.g., Alzheimer's disease, Parkinson's disease, Huntington's chorea, frontotemporal dementia) in the medical records;
* Recent diagnosis of cerebral conditions (\<1 year e.g. cerebral infarction, hemorrhage, brain tumors, transient ischemic attack) in the medical records;
* Any medical condition that significantly interferes with digestion and/or gastrointestinal function (e.g. short bowel syndrome, inflammatory bowel disease, gastric ulcers, gastritis, (gastro)-enteritis, GI-cancer) as judged by the investigator.
* Diagnosis of any chronic lung disease.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No